Atrial Fibrillation

As Many as 1 in 3 High-risk Patients with Atrial Fibrillation are Not Prescribed Anticoagulation
November 18, 2022

The low rate of stroke prevention with oral anticoagulation in patients with atrial fibrillation is cause for significant concern, say investigators.

Apixaban May be the Safer DOAC in Afib, Suggests First Large Comparative Analysis
November 04, 2022

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

Black Patients with Afib Significantly Less Likely to Receive Oral Anticoagulation at Hospital Discharge
October 31, 2022

Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.

The Daily Dose: Dueling DOACS
October 20, 2022

Your daily dose of the clinical news you may have missed.

Apixaban Found More Effective than Rivaroxaban in Patients with AFib and Valvular Heart Disease
October 19, 2022

In the absence of randomized controlled head-to-head trials comparing the 2 anticoagulants, study authors say clinicians should consider their findings when choosing treatment.

Migraine with Aura Characterized as Independent Risk Factor for Atrial Fibrillation
September 22, 2022

Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.

Hypertension-related CVD Most Common ED Presentation in the US
September 21, 2022

Approximately one-third of CV-related ED visits are for hypertension-related conditions, including 13% for essential hypertension among women.

Intervention Reduces Aspirin Use in Patients with AF, VTE Taking Warfarin, Improves Outcomes
September 21, 2022

An aspirin deprescribing intervention at anticoagulation clinics led to a 50% reduction in use among patients with AF, VTE prescribed warfarin.

Abelacimab Receives Fast Track Designation from FDA for Prevention of Stroke, Systemic Embolism in Patients with Atrial Fibrillation
September 09, 2022

Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.

Wrist-worn Devices Prove Cost-effective for AF Screening of 30 Million in Economic Simulation
August 10, 2022

Screening for atrial fibrillation with 6 wrist-worn wearable devices proved more cost effective than no screening and had greater relative benefit than using traditional modalities.